TGTX

TG Therapeutics, Inc. - Common Stock (TGTX)

About TG Therapeutics, Inc. - Common Stock (TGTX)

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Details

Daily high

$58.92

Daily low

$56.00

Price at open

$57.23

52 Week High

$59.30

52 Week Low

$26.76

Market cap

8.7B

Dividend yield

Volume

1.6M

Avg. volume

1.8M

P/E ratio

20.71

TG Therapeutics, Inc. - Common Stock News